Melody Smith, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Smith’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C175292 · Current
Licensed to practise in California · since 2021 · expires 2027-10-31 · University of Texas Southwestern Medical School at Dallas.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$28,035
Medicare paid this office $28,035 for 56 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $14,660 | $105 |
| Long return visit (40+ min) | 27 | $9,024 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,849 | $154 |
Who their Medicare patients are
56 Original Medicare patients in 2024. Average age 72 · Women 55% · Health risk score 2.91. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 73% · Chronic kidney disease 38% · Atrial fibrillation 29% · Diabetes 27% · Coronary heart disease 25% · Cancer 20% · Depression 20%.
The office billed $86,186, Medicare allowed $35,161 and paid $28,035; for 239 services of 7 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 56 | 239 | 72 | 2.91 | $86,186 | $28,035 |
| 2023 | 49 | 201 | 68 | 3.59 | $83,140 | $23,261 |
| 2022 | 38 | 212 | 69 | 2.22 | $85,562 | $22,100 |
| 2021 | 14 | 152 | 64 | 3.84 | $76,480 | $14,362 |
| 2020 | 17 | 112 | 67 | 5.00 | $55,265 | $10,312 |
| 2019 | 41 | 181 | 68 | 2.94 | $101,280 | $17,597 |
| 2018 | 24 | 80 | 70 | 4.36 | $37,990 | $7,368 |
| 2017 | 12 | 103 | 65 | 3.48 | $51,565 | $9,588 |
| 2016 | 29 | 193 | 65 | 2.94 | $92,025 | $17,955 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $14,541 | $108 |
| Long return visit (40+ min) | 23 | $5,185 | $130 |
2022: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $13,771 | $93 |
| Long return visit (40+ min) | 13 | $4,569 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,984 | $180 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,170 | $98 |
2021: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $14,131 | $95 |
2020: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $8,874 | $96 |
2019: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $12,338 | $93 |
| Hospital discharge day management, 30 minutes or less | 11 | $793 | $66 |
2018: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $6,306 | $93 |
2017: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $8,622 | $91 |
2016: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $15,621 | $92 |
Drugs they prescribed that Part D paid
$19,658
Pharmacies billed $19,658 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
88 generic and fewer than 11 brand-name prescriptions · $19,658 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Acyclovir | 31 | $576 | $19 |
| Lorazepam | 11 | $75 | $7 |
Year by year
| 2024 | 97 | 15 | None | None | $19,658 |
| 2023 | 48 | 12 | 0% (0) | None | $13,653 |
| 2014 | 12 | None | 0% (0) | 0% | $189 |
| 2013 | 48 | 18 | 0% (0) | None | $6,181 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Acyclovir | 15 | $404 | $27 |
Money from drug and device companies
$427 in 2025
| 2025 | 3 | 4 | None | $427 |
| 2024 | 4 | 4 | None | $456 |
| 2023 | 4 | 5 | $675 | $19,014 |
| 2022 | 5 | 6 | $1,329 | $1,783 |
| 2021 | 1 | 1 | $4,290 | $4,290 |
| 2019 | 1 | 1 | None | $148 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Kite Pharma | None | $283 | 2 payments
|
| Gilead Sciences | Yescarta | $121 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $23 | 1 payment
|
See all 4 published payments
| Kite Pharma | Meals · 2025-12-07 | None | $167 |
| Adaptive Biotechnologies | Meals · 2025-04-30 | Clonoseq | $23 |
| Kite Pharma | Meals · 2025-02-14 | None | $116 |
| Gilead Sciences | Meals · 2025-02-12 | Yescarta | $121 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $456
| Sobi | Gamifant | $151 | 1 payment
|
| Celgene | None | $125 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $115 | 1 payment
|
| Abbott Laboratories | Cardiomems | $65 | 1 payment
|
2023: $19,014
| Genentech | None | $18,182 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $735 | 2 payments
|
| National Marrow Donor Program | None | $75 | 1 payment
|
| Kite Pharma | Yescarta | $22 | 1 payment
|
2022: $1,783
| E.R. Squibb & Sons L.L.C. | None | $1,329 | 1 payment
|
| Celgene | None | $130 | 2 payments
|
| Kite Pharma | None | $125 | 1 payment
|
| Incyte | Monjuvi | $125 | 1 payment
|
| Novartis Pharmaceuticals | Kymriah | $74 | 1 payment
|
2021: $4,290
| Janssen Research & Development | None | $4,290 | 1 payment
|
2019: $148
| Eli Lilly and | None | $148 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790915031
- Licence
- AR C175292, CA C175292, NY 265523California C175292: Current · expires 2027-10-31
- Trained
- University of Texas Southwestern Medical School at Dallas, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Medical oncology (207RX0202X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-07-21
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.